Also, the serum levels of TGF-β1 are known to increase following tumour progression in patients with colorectal carcinoma [37], prostatic cancer [38], and breast cancer [39]; and such increase is frequently associated with poor prognosis [40]. Here, TGFB1 is linked to prostate carcinoma.